In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and maintenance of quality of life.

Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads.

2 Currently, standard first-line treatment for advanced or recurrent endometrial cancer often involves platinum-based chemotherapy, frequently in combination with immunotherapy agents like ...

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

As diagnoses climb and innovation accelerates, major federal funding cuts are forcing a shift toward private biotech - and ...

A perfect storm of scientific, economic, and cultural barriers are holding back immunotherapy's true potential, writes Samir ...

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.